Spinraza (Nusinersen) Denied: Appealing SMA Coverage for Spinal Muscular Atrophy

Spinraza (nusinersen) is an antisense oligonucleotide therapy FDA-approved for spinal muscular atrophy (SMA) in pediatric and adult patients. It was the first disease-modifying treatment for SMA approved in the United States, in 2016, and it works by modifying SMN2 pre-mRNA splicing to increase functional SMN protein production. Spinraza is administered intrathecally (via lumbar puncture) and costs approximately $125,000 per dose, making it one of the most expensive regularly dosed medications in the US. This cost structure makes insurance denials particularly consequential — and particularly common.

Why Spinraza Gets Denied

SMA type criteria disputes. Spinraza is FDA-approved for all types of SMA (Type 1, 2, 3, and 4) and for pre-symptomatic patients diagnosed by newborn screening. However, insurer coverage policies are not always as broad as the FDA label. Some payers restrict coverage to SMA Type 1 or Type 2, denying treatment for higher-functioning Type 3 or Type 4 adults. These restrictions are inconsistent with the FDA-approved label and are challengeable.

Age limitation policies. Some commercial insurers have imposed age caps on Spinraza coverage — for example, limiting coverage to patients under 18 — even though the FDA label does not contain such restrictions. Adult SMA patients face particularly high Denial Rates by Insurer (2026)" class="auto-link">denial rates despite having a diagnosed SMN1 mutation and documented progressive weakness.

Functional status cutoffs. Certain payers use functional measures (CHOP INTEND score, HFMSE score, RULM) to determine eligibility and, controversially, to discontinue coverage if a patient does not show improvement by a certain threshold. Denials for "lack of effectiveness" based on functional plateau arguments are among the most contested — the neuromuscular disease community argues that stabilization (preventing further decline) is a valid treatment outcome in a progressive neurodegenerative disease.

Competition with Zolgensma and Evrysdi. Since the approval of onasemnogene abeparvovec (Zolgensma) for SMA Type 1 in patients under 2 years old, and risdiplam (Evrysdi) as an oral alternative, some insurers have created treatment pathway requirements. For newly diagnosed infants, the insurer may push toward Zolgensma as a one-time treatment. For older patients, Evrysdi's oral administration may be preferred. Appeals must address why Spinraza specifically is indicated for the individual patient.

Building Your Spinraza Appeal

Establish diagnosis with genetic testing. Your appeal should confirm biallelic SMN1 deletion or pathogenic variant documented by genetic testing, SMN2 copy number, and the patient's SMA type and clinical presentation. Copy number matters: fewer SMN2 copies correlate with more severe disease.

Address the functional status argument. If the denial is based on lack of demonstrated functional improvement, your neurologist's letter should argue:

• SMA is a progressive disease; disease stabilization — preventing loss of motor function, respiratory function, or swallowing — is a clinically meaningful outcome
• Published long-term data from SHINE and NURTURE extension trials demonstrate sustained benefit including in patients with stable function
• Functional decline attributable to Spinraza cessation can be rapid and irreversible

Age and type restrictions are off-label policies. If the insurer's policy restricts Spinraza by age or SMA type beyond what the FDA label allows, the appeal should explicitly state that the policy is more restrictive than the FDA-approved labeling and cite the label directly.

Compare to alternatives. For patients who are not candidates for Zolgensma (age > 2 years, excess weight, anti-AAV9 antibodies) or Evrysdi (drug interactions, intolerance, or patient/family preference for intrathecal delivery with established CNS access), document these specifics.

Handling Insurer Requests to Switch to Evrysdi

Some insurers prefer Evrysdi (risdiplam) because it is an oral drug with lower administration burden. If you are on Spinraza and being pushed to switch to Evrysdi, the appeal should address:

• Established clinical response on Spinraza
• Risk of disease activity during any transition period
• Patient-specific factors (intrathecal delivery preference, monitoring infrastructure already in place, participation in Spinraza long-term extension study)
• The absence of head-to-head trial data comparing Spinraza and Evrysdi in your specific SMA type

Fight Back With ClaimBack

Spinraza denials affect patients with one of the most serious rare diseases in medicine. The cost of denial can be irreversible neurological decline. ClaimBack helps SMA patients and families build the most precise, evidence-backed appeals possible.

Start your Spinraza appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?